InfuSystem Holdings, Inc.(INFU)Earnings, Financials & Key RatiosInfuSystem Holdings, Inc. (INFU) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully deleveraged its balance sheet to a 0.39 debt-to-equity ratio, the recent -3.0% revenue decline and inconsistent free cash flow margins warrant a cautious wait-and-see approach.
InfuSystem Holdings, Inc. (INFU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
InfuSystem Holdings, Inc. (INFU) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.04+25.0% | $34Mvs $34M-1.9% |
| Q1 2026 | Feb 24, 2026 | $0.10vs $0.07+42.9% | $36Mvs $37M-1.2% |
| Q4 2025 | Nov 4, 2025 | $0.11vs $0.08+37.5% | $36Mvs $37M-0.5% |
| Q3 2025 | Aug 5, 2025 | $0.12vs $0.03+300.0% | $36Mvs $37M-3.7% |
Recent stock market news and headlines for InfuSystem Holdings, Inc. (INFU)
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InfuSystems Holdings (INFU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
InfuSystem is rated a buy, leveraging a stable oncology-focused patient services segment with strong FCF yields, margin progress, and reasonable valuations. INFU offers an attractive FCF yield of 11.6%, nearly double its peer Viemed Healthcare, and trades at a reasonable forward EV/EBITDA multiple below 6.5x. Management's future financial outlook is supported by reduced Capex, ERP-driven efficiencies, and growth in low-capital-intensive segments like wound care.
Key metrics vs top competitors for InfuSystem Holdings, Inc. (INFU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.69 | $195.56M | 31.26 | 6.36% | 4.62% | 11.54% | — | |
| $14.87 | $279.89M | -22.53 | 1.46% | -12.52% | -6.77% | — | |
| $24.39 | $1.67B | 30.11 | 7.08% | 3.67% | 13.6% | — | |
| $6.29 | $118.03M | 23.30 | 18.78% | 6.37% | 5.47% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $44.36 | $2.02B | 1001.35 | 6.53% | 1.67% | 1.64% | — |
InfuSystem Holdings, Inc. (INFU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
InfuSystem Holdings, Inc. (INFU) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
May 14, 2026·SEC
May 12, 2026·SEC
Get notified when INFU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
InfuSystem Holdings, Inc. (INFU) stock FAQ — growth, dividends, profitability & financials explained
InfuSystem Holdings, Inc. (INFU) reported $142.4M in revenue for fiscal year 2025.
InfuSystem Holdings, Inc. (INFU) grew revenue by 6.4% over the past year. This is steady growth.
Yes, InfuSystem Holdings, Inc. (INFU) is profitable, generating $7.9M in net income for fiscal year 2025 (4.6% net margin).
InfuSystem Holdings, Inc. (INFU) has a return on equity (ROE) of 11.5%. This is reasonable for most industries.
InfuSystem Holdings, Inc. (INFU) generated $20.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
